Phathom Pharmaceuticals (Nasdaq: PHAT) announced it has completed patient enrollment in its Phase 2 pHalcon-EoE-201 clinical trial, which is evaluating ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE